Scheme 1. Retrosynthetic Analysis
Figure 1. Molecular structures of liposidomycins.
in vitro with an ID50 of 0.03 µg/mL.7 In addition to these
prominent biological properties, the liposidomycins offer
attractive structural features, characterized by a 3,6,7-
trisubstituted-1,4-dimethyldiazepan-2-one system, which is
linked to a uridine nucleoside moiety through a carbon
bridge. Located at this carbon, we find a hydroxyl group,
which is linked to a 5-deoxy-5-amino-ribofuranosyl residue
by a glycosidic bond.8 Despite the liposidomicins general
structure having been previously elucidated, the absolute
configurations of the indicated chiral centers in Figure 1,
located in the diazepanone ring and in the exo-OH domains,
remain unnassigned.9 Nevertheless, recent synthetic studies
conducted by Knapp et al. have suggested that the configura-
tions at C-5′ and C-6′ are (S).10 Similarly, configurations at
C-2′′′ and C-3′′′ have been tentatively established as 2′′′S
and 3′′′S through further synthetic studies.11 All these
structural features, in conjunction with the biological proper-
ties of liposidomycins, compelled us to embark on a program
aimed at the total synthesis of these natural nucleosides. In
the present paper, we wish to report the first synthetic studies
directed toward the synthesis of the diazepanone core
structure of the liposidomycins, based on the chemistry of
sulfur ylides, which is well suited to the preparation of not
only the natural antibiotics but also of potentially bioactive
analogues.12
diazepanone ring. According to this, the liposidomycins
would initially be disconnected at the glycosydic site to
obtain the corresponding donor derived from 5-deoxy-5-
amino-D-ribose and the acceptor compound 4. The second
major retrosynthetic disconnection is at the N1-C2 bond of
compound 4 to generate epoxyamide 5, which would give
rise to the corresponding diazepanone derivative 4 via an
intramolecular 7-exo-tet cyclization reaction. Finally, ep-
oxyamide 5 could be prepared from the corresponding
aldehyde 6 by reaction with the sulfur ylide 7, which would
contain the suitable functionality present in the diazepanone
ring.
Our initial synthetic studies were focused on a model
compound to prove the efficiency of the designed strategy.
Therefore, we commenced with the synthesis of the sulfo-
nium salt 9 by conventional methods.13 The reaction of
aldehyde 614 with the corresponding sulfur ylide derived from
9 was performed by two different procedures: (a) the one-
phase method, in which the ylide was previously prepared,
and (b) the two-phase method,15 in which the ylide was
generated in situ by treatment of 9 with an aqueous sodium
hydroxide solution. In both cases, the epoxide 10 was
obtained in 67% yield and high diastereoselectivity, ap-
1
proximately 90:10 according to the H NMR spectra. The
configurations for the new two chiral centers of the oxirane
Scheme 1 outlines briefly the retrosynthetic analysis of
the liposidomycin core, using sulfur ylides to construct the
(12) Analogues of the liposidomycins: (a) Dini, C.; Collete, P.; Drochon,
N.; Guillot, J. C.; Lemoine, G.; Mauvais, P.; Aszodi, J. Bioorg. Med. Chem.
Lett. 2000, 10, 1839-1843. (b) Dini, C.; Drochon, N.; Feteanu, S.; Guillot,
J. C.; Peixoto, C.; Aszodi, J. Bioorg. Med. Chem. Lett. 2001, 11, 529-
531. (c) Dini, C.; Drochon, N.; Guillot, J. C.; Mauvais, P.; Walter, P.;
Aszodi, J. Bioorg. Med. Chem. Lett. 2001, 11, 533-536. (d) Dini, C.; Didier-
Laurent, S.; Drochon, N.; Feteanu, S.; Guillot, J. C.; Monti, F.; Uridat, E.;
Zhang, J.; Aszodi, J. Bioorg. Med. Chem. Lett. 2002, 12, 1209-1213.
(13) Lo´pez Herrera, F. J.; Sarabia Garc´ıa, F.; Heras Lo´pez, A.; Pino
Gonza´lez, M. S. J. Org. Chem., 1997, 62, 6056-6059 and references therein.
(14) Danishefsky, S. J.; DeNinno, S. L.; Chen, S.-h.; Boisvert, L.;
Barbachyn, M. J. Am. Chem. Soc. 1989, 111, 5810-5818.
(7) (a) Kimura, K.-I.; Miyata, N.; Kawanishi, G.; Kamio, Y.; Izaki, K.;
Isono, K. Agric. Biol. Chem. 1989, 53, 1811-1815. (b) Muroi, M.; Kimura,
K.-I.; Osada, H.; Inukai, M.; Takatsuki, A. J. Antibiot. 1997, 50, 103-104.
(c) Kimura, K.-I.; Ikeda, Y.; Kagami, S.; Yoshihama, M.; Suzuki, K.; Osada,
H.; Isono, K. J. Antibiot. 1998, 51, 1099-1104.
(8) Knapp, S.; Morriello, G. J.; Doss, G. A. Tetrahedron Lett. 2002, 43,
5797-5800 and references therein.
(9) Knapp, S.; Morriello, G. J.; Nandan, S. R.; Emge, T. J.; Doss, G.
A.; Mosley, R. T.; Chen, L. J. Org. Chem. 2001, 66, 5822-5831.
(10) Knapp, S.; Morriello, G. J.; Doss, G. A. Org. Lett. 2002, 4, 603-
606.
(11) Nakajima, N.; Isobe, T.; Irisa, S.; Ubukata, M. Heterocycles 2003,
59, 107-113.
(15) Lo´pez Herrera, F. J.; Pino Gonza´lez, M. S.; Sarabia Garc´ıa, F.; Heras
Lo´pez, A.; Ortega Alca´ntara, J. J.; Pedraza Cebria´n, M. G. Tetrahedron:
Asymmetry 1996, 7, 2065.
3928
Org. Lett., Vol. 5, No. 21, 2003